In adults with overweight or obesity, with or without T2D and without known major psychopathology, weekly subcutaneous tirzepatide for 72 weeks is not linked to an increased risk for depression.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/no-mental-harm-tirzepatide-weight-management-2026a10002mt?src=rss
Author :
Publish date : 2026-01-28 04:50:00
Copyright for syndicated content belongs to the linked Source.
